![](/img/cover-not-exists.png)
PCN115 COMPARISON OF ADVERSE EVENT COSTS OF NIVOLUMAB+IPILIMUMAB VERSUS SUNITINIB FOR PREVIOUSLY UNTREATED INTERMEDIATE-/POOR-RISK ADVANCED RENAL CELL CARCINOMA IN SPAIN
Polanco Sánchez, C., Gooden, K.M., May, J., Malcolm, B., Du, E.X., Yin, L., Betts, K.Volume:
22
Journal:
Value in Health
DOI:
10.1016/j.jval.2019.09.312
Date:
November, 2019
File:
PDF, 382 KB
2019